Vobarilizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Vobarilizumab
Monoclonal antibody
Type Single-chain variable fragment
Source Humanized
Target IL6R
Clinical data
Synonyms ALX0061
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C1118H1757N315O364S8
Molar mass 256.9 kDa

Vobarilizumab (ALX0061) (INN) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.[1][2]

This drug was developed by Ablynx NV.

References[edit]